Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639063 | 0.92 | BRD4 (0.45) | GPR119ESR2NR1H2KDM1AUCHL1 | |
| SCHEMBL26609193 | 0.89 | CHRM4 (0.43) | GPR119CHRM4DRD2HTR7ESR2 | |
| SCHEMBL19639057 | 0.81 | BRD4 (0.42) | GPR119CHRM4DRD2HTR7ESR2 | |
| SCHEMBL30900483 | 0.80 | NOTUM (0.61) | KDM1ANOTUMNPC1RAB9AL3MBTL1 | |
| SCHEMBL552069 | 0.80 | NOTUM (0.61) | KDM1ANOTUMNPC1RAB9AL3MBTL1 | |
| SCHEMBL1165734 | 0.79 | NOTUM (0.60) | NOTUMNPC1RAB9A | |
| SCHEMBL952312 | 0.77 | ESR2 (0.62) | GPR119ESR2NR1H2HDAC1 | |
| SCHEMBL3899182 | 0.76 | ESR2 (0.61) | GPR119CHRM4DRD2HTR7ESR2 | |
| SCHEMBL8200750 | 0.76 | NOTUM (0.64) | GPR119DRD2ESR2DHODHNOTUM | |
| SCHEMBL13656966 | 0.76 | GPR119 (0.47) | GPR119DRD2ESR2DHODHNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190119277-A1 | VINBLASTINE 20' AMIDES: SYNTHETIC ANALOGS THAT MAINTAIN OR IMPROVE POTENCY AND SIMULTANEOUSLY OVERCOME Pgp-DERIVED EFFLUX AND RESISTANCE | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | ABCG2, ABCC1, GLS | GPR119 3327/4885CHRM4 3872/4885DRD2 259/4885 |
| US-20190119277-A1 | VINBLASTINE 20' AMIDES: SYNTHETIC ANALOGS THAT MAINTAIN OR IMPROVE POTENCY AND SIMULTANEOUSLY OVERCOME Pgp-DERIVED EFFLUX AND RESISTANCE | ABCG2, ABCC1, GLS | GPR119 3336/4885CHRM4 3881/4885DRD2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.